Glaucocalyxin B
Based on 1 publication(s) in Google Scholar
Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an IC50 of approximately 5.86 μM at 24 h.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.83%
- CAS No.: 80508-81-2
- Formule: C22H30O5
- Masse moléculaire:374.47
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Glaucocalyxin B
More
Activité biologique
Description
IC50 & Target
IC50: 5.86 μM (HL-60 cell Growth)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
6.22 μM
Compound: 19
|
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| MCF7 | IC50 |
>10 μM
Compound: 19
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| NB-4 | IC50 |
7.86 μM
Compound: 19
|
Cytotoxicity against human NB4 cells after 48 hrs by SRB method
Cytotoxicity against human NB4 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| PC-3 | IC50 |
>10 μM
Compound: 19
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| SH-SY5Y | IC50 |
>10 μM
Compound: 19
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method
Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method
|
[PMID: 19425589] |
In Vitro
Glaucocalyxin A (GlnA) and (GlnB) dose-dependently decrease the growth of HL-60 cells with an IC50 of approximately 6.15 and 5.86 μM at 24 h, respectively. Both Gln A and B could induce apoptosis, G2/M-phase cycle arrest, DNA damage and the accumulation of reactive oxygen species (ROS) in HL-60 cells[1]. GlnB inhibits the proliferation of human cervical cancer cells in vitro through the induction of apoptosis andautophagy, which may be mediated by the phosphatidylinositol 4,5 bisphosphate 3 kinase/Akt signaling pathway. Treatment with GlnB inhibits the proliferation of HeLa and SiHa cervical cancer cell lines in a dose dependent manner. GlnB increases the apoptotic cell population of and enhanced poly (ADP ribose) polymerase 1 cleavage. GlnB also induces increased light chain 3 II/I protein cleavage, indicating the induction of autophagy. GlnB treatment increases the expression of phosphatase and tensin homolog and decreases the expression of phosphorylated protein kinase B[2]. Glaucocalyxin B (GLB), one of five ent-kauranoid diterpenoids, significantly decreased the generation of nitric oxide (NO), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) in the lipopolysaccharide (LPS)-activated microglia cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 80508-81-2
-
Appearance Solid
-
Masse moléculaire 374.47
-
Formule C22H30O5
-
Color White to off-white
-
SMILES
CC1(C)C(CC[C@@]2(C)[C@@]3([H])[C@@]4(C(C([C@H](CC3)[C@H]4OC(C)=O)=C)=O)[C@H](O)C[C@]12[H])=O
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Can J Diabetes
Glaucocalyxin B Attenuates Diabetic Cardiomyopathy by Suppressing the NLRP3 Inflammasome and Restoring Gut Microbiota Homeostasis. [Abstract]2026 Feb 6:S1499-2671(26)00029-8. PMID: 41655638
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (267.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yang WH, et al. Glaucocalyxin A and B-induced cell death is related to GSH perturbation in human leukemia HL-60 cells. Anticancer Agents Med Chem. 2013 Oct;13(8):1280-90. [Content Brief]
[2]. Pan Y, et al. Glaucocalyxin B induces apoptosis and autophagy in human cervical cancer cells. Mol Med Rep. 2016 Aug;14(2):1751-5. [Content Brief]
[3]. Gan P, et al. Anti-inflammatory effects of glaucocalyxin B in microglia cells. J Pharmacol Sci. 2015 May;128(1):35-46. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6704 mL | 13.3522 mL | 26.7044 mL | 66.7610 mL |
| 5 mM | 0.5341 mL | 2.6704 mL | 5.3409 mL | 13.3522 mL | |
| 10 mM | 0.2670 mL | 1.3352 mL | 2.6704 mL | 6.6761 mL | |
| 15 mM | 0.1780 mL | 0.8901 mL | 1.7803 mL | 4.4507 mL | |
| 20 mM | 0.1335 mL | 0.6676 mL | 1.3352 mL | 3.3381 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0682 mL | 2.6704 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8901 mL | 2.2254 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6690 mL | |
| 50 mM | 0.0534 mL | 0.2670 mL | 0.5341 mL | 1.3352 mL | |
| 60 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL | |
| 80 mM | 0.0334 mL | 0.1669 mL | 0.3338 mL | 0.8345 mL | |
| 100 mM | 0.0267 mL | 0.1335 mL | 0.2670 mL | 0.6676 mL |
Glaucocalyxin B Related Classifications
HY-N2113 Related Classifications
Powered by Bioz